XTL Biopharmaceuticals Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XTLB research report →
Companywww.xtlbio.com
XTL Biopharmaceuticals Ltd. , a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
- CEO
- Noam Band
- IPO
- 2005
- Employees
- 10
- HQ
- Ramat Gan, IL
Price Chart
Valuation
- Market Cap
- $6.08M
- P/E
- -4.30
- P/S
- 13.77
- P/B
- 0.81
- EV/EBITDA
- -6.43
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.67%
- Op Margin
- -481.60%
- Net Margin
- -227.72%
- ROE
- -26.83%
- ROIC
- -29.75%
Growth & Income
- Revenue
- $451.00K · 0.00%
- Net Income
- $-1,027,000 · -57531.87%
- EPS
- $-9.60 · 0.00%
- Op Income
- $-2,172,000
- FCF YoY
- -136.49%
Performance & Tape
- 52W High
- $10.28
- 52W Low
- $2.12
- 50D MA
- $2.63
- 200D MA
- $3.78
- Beta
- 0.71
- Avg Volume
- 1.95M
Get TickerSpark's AI analysis on XTLB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Hillel Fain Osnat | other | 1,000,000 |
| Mar 18, 26 | Segal Niv | other | 0 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 24,681,360 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 2,696,450 |
| Nov 19, 08 | EDELMAN JOSEPH | sell | 9,600,000 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 29,740 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 400,000 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 1,943,250 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 400,000 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 299,570 |
Our XTLB Coverage
We haven't published any research on XTLB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XTLB Report →